Market Place
Sourcing Support
Centessa drops hemophilia B drug following Pfizer’s Hympavzi win
13 Nov 2024 //
FIERCE BIOTECH
Centessa Pharma Reports Financial Results for Q3 of 2024
12 Nov 2024 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Centessa Presents ORX142 Data At Sleep Europe 2024
26 Sep 2024 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Prices $225 Million Public Offering
12 Sep 2024 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of ADSs
11 Sep 2024 //
GLOBENEWSWIRE
Centessa Reports Positive ORX750 Phase 1 Interim Data
10 Sep 2024 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces Presentation On ORX142 At Sleep Europe
27 Aug 2024 //
GLOBENEWSWIRE
Centessa To Participate In Morgan Stanley Healthcare Conference
21 Aug 2024 //
GLOBENEWSWIRE
Centessa Pharma Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Centessa Appoints John Crowley As CFO, Gregory Weinhoff As CBO
10 Jun 2024 //
GLOBENEWSWIRE
Nxera To Receive $4.6M Milestones From Centessa
30 May 2024 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
21 May 2024 //
GLOBENEWSWIRE
Centessa Pharma Q1 2024 Financials, Business Highlights
13 May 2024 //
GLOBENEWSWIRE
Centessa Announces $100M Proposed Public ADS Offering
23 Apr 2024 //
GLOBENEWSWIRE
Centessa Prices $100M Public ADS Offering
23 Apr 2024 //
GLOBENEWSWIRE
Centessa IND For ORX750, Sleep-Deprived POC In 2H24
22 Apr 2024 //
GLOBENEWSWIRE
Biotech naming trends bypass `buzzwords and business speak`
16 Apr 2024 //
FIERCE BIOTECH
Centessa Pharmaceuticals Reports Business Highlights and Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Centessa to Participate in TD Cowen™s 44th Annual Health Care Conference
22 Feb 2024 //
GLOBENEWSWIRE
Centessa to Present Data from Third Year of Phase 2a Study of SerpinPC
09 Feb 2024 //
GLOBENEWSWIRE
Centessa to Present at the 42¿áµˆ Annual J.P. Morgan Healthcare Conference
13 Dec 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces New Data from Phase 2a Study of SerpinPC
10 Dec 2023 //
GLOBENEWSWIRE
Anaptys Expands Immune Cell Modulator Pipeline
27 Nov 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2023
13 Nov 2023 //
GLOBENEWSWIRE
Centessa to Present Data from Third Year of Ongoing Phase 2a Study of SerpinPC
02 Nov 2023 //
GLOBENEWSWIRE
Centessa Announces Dosing of First Subject in Study Evaluating SerpinPC
31 Oct 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750 Potential
25 Oct 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
03 Oct 2023 //
GLOBENEWSWIRE
Centessa Pharma to Participate in the Morgan Stanley 21st Annual Conference
31 Aug 2023 //
GLOBENEWSWIRE
Centessa to Present Data for Novel OX2R Agonist at World Sleep Congress
23 Aug 2023 //
GLOBENEWSWIRE
Centessa Pharma Reports Financial Results for the Second Quarter of 2023
14 Aug 2023 //
GLOBENEWSWIRE
Centessa Announces Dosing of First Subject in Registrational PRESent-2 Study
10 Jul 2023 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
24 May 2023 //
GLOBENEWSWIRE
Centessa Receives Fast Track Designation from FDA for SerpinPC for Hemophilia B
22 May 2023 //
GLOBENEWSWIRE
Centessa Reports Financial Results for the First Quarter of 2023
12 May 2023 //
GLOBENEWSWIRE
Centessa Reports Financial Results for the 4Q and Full-Year 2022
30 Mar 2023 //
GLOBENEWSWIRE
Centessa Pharma Announces Addition of Patrick Yue, MD, as SVP of Clinical DevP
01 Mar 2023 //
GLOBENEWSWIRE
Centessa to Present Data from OLE of Ph2a of SerpinPC for Hemophilia at EAHAD
06 Feb 2023 //
GLOBENEWSWIRE
Centessa Announces Presentation at SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
Centessa Announces FDA Clearance of IND Application for Ph 1/2a Trial of LB101
26 Jan 2023 //
GLOBENEWSWIRE
Centessa Announces 18-Months of Continued Treatment Data from OLE of Phase 2a
10 Dec 2022 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
30 Nov 2022 //
GLOBENEWSWIRE
Centessa Reports Financial Results and Business Highlights for the 3Q 2022
10 Nov 2022 //
GLOBENEWSWIRE
Centessa Pharma to Present Additional 18-Months of Continued Treatment Data
03 Nov 2022 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
31 Oct 2022 //
GLOBENEWSWIRE
Centessa Announces Poster Presentation Featuring Novel Orexin Receptor 2
20 Sep 2022 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC
14 Sep 2022 //
GLOBENEWSWIRE
Centessa Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101
12 Sep 2022 //
GLOBENEWSWIRE
ROSEN Encourages Centessa Pharma Investors About Class Action Investigation
25 Aug 2022 //
PRNEWSWIRE
Centessa Pharmaceuticals Reports Financial Results for the Q2 of 2022
10 Aug 2022 //
GLOBENEWSWIRE
Centessa Pharma Announces Addition of Harris L. Rotman, PhD, as Senior VP
25 Jul 2022 //
GLOBENEWSWIRE
Centessa Pharma Appoints Dr. Mathias Hukkelhoven to its Board of Directors
01 Jul 2022 //
GLOBENEWSWIRE
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
06 Jun 2022 //
GLOBENEWSWIRE
Centessa Announces Poster Presentation of First PC Data for LockBody Program
05 Jun 2022 //
GLOBENEWSWIRE
Centessa Pharma To No Longer Develop Lixivaptan For Treatment Of ADPKD
03 Jun 2022 //
NASDAQ
Centessa Pharma to Discontinue Clinical Development of Lixivaptan in ADPKD
02 Jun 2022 //
GLOBENEWSWIRE
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Centessa Pharma Reports Q4 and 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
